KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Receivables (2016 - 2025)

Boston Scientific's Receivables history spans 17 years, with the latest figure at $3.1 billion for Q4 2025.

  • For Q4 2025, Receivables rose 14.66% year-over-year to $3.1 billion; the TTM value through Dec 2025 reached $3.1 billion, up 14.66%, while the annual FY2025 figure was $3.1 billion, 14.66% up from the prior year.
  • Receivables for Q4 2025 was $3.1 billion at Boston Scientific, up from $3.0 billion in the prior quarter.
  • Across five years, Receivables topped out at $3.1 billion in Q4 2025 and bottomed at $1.6 billion in Q1 2021.
  • The 5-year median for Receivables is $2.2 billion (2023), against an average of $2.3 billion.
  • The largest YoY upside for Receivables was 23.19% in 2021 against a maximum downside of 1.98% in 2021.
  • A 5-year view of Receivables shows it stood at $1.9 billion in 2021, then increased by 4.45% to $2.0 billion in 2022, then increased by 13.1% to $2.2 billion in 2023, then increased by 19.7% to $2.7 billion in 2024, then grew by 14.66% to $3.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Receivables are $3.1 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.8 billion (Q2 2025).